GEORGE M SHAW, MD
Osteopathic Medicine at 19 St, Birmingham, AL

2014002, Jan 23, 2014

Sep 8, 2011

13/821886

George M. Shaw - Birmingham AL, US
Hui Li - Birmingham AL, US
Beatrice H. Hahn - Birmingham AL, US
Barton F. Haynes - Durham NC, US

THE UAB RESEARCH FOUNDATION - Birmingham AL
DUKE UNIVERSITY - Durham NC

C12Q 1/70, A61K 39/29

4242281, 435 5, 536 2372

This invention provides methods for identifying HCV genomes and more specifically, methods for identifying nucleotide sequence of viral structural proteins at the time of HCV viral transmission. The method of the invention utilizes single genome amplification and sequencing of circulating virus as well as phylogenetic analysis of the resulting nucleotide sequence for identifying transmitted HCV genomes. Also provided are HCV genomes and corresponding nucleotide sequence for transmitted and circulating HCV virus. The invention further provides methods of administering a vaccine comprising one or more identified transmitted HCV sequences.

8071107, Dec 6, 2011

Sep 17, 2004

10/572638

Barton F. Haynes - Durham NC, US
Feng Gao - Durham NC, US
Bette T. Korber - Los Alamos NM, US
Beatrice H. Hahn - Birmingham AL, US
George M. Shaw - Birmingham AL, US
Denise Kothe - Birmingham AL, US
Ying Ying Li - Hoover AL, US
Julie Decker - Alabaster AL, US

Duke University - Durham NC
The Regents of the University of California - Oakland CA
The University of Alabama at Birmingham Research Foundation - Birmingham AL

A61K 39/21, C07H 21/04

4242081, 536 2372

The present invention relates, in general, to an immunogen and, in particular, to an immunogen for inducing antibodies that neutralizes a wide spectrum of HIV primary isolates and/or to an immunogen that induces a T cell immune response. The invention also relates to a method of inducing anti-HIV antibodies, and/or to a method of inducing a T cell immune response, using such an immunogen. The invention further relates to nucleic acid sequences encoding the present immunogens.

8637234, Jan 28, 2014

Apr 8, 2005

11/578761

George M. Shaw - Birmingham AL, US
James E. Robinson - New Orleans LA, US
Frederic Bibollet-Ruche - Birmingham AL, US
Julie M. Decker - Alabaster AL, US
Beatrice H. Hahn - Birmingham AL, US
Peter D. Kwong - Bethesda MD, US

UAB Research Foundation - Birmingham AL
The Administrators of Tulane Educational Fund - New Orleans LA
The United States of America, as represented by the Secretary, Department of Health and Human Services - Washington DC

C12Q 1/70, A61K 39/00, A61K 39/12, A61K 39/21, A61K 39/38, C07K 16/00

435 5, 435339, 4353391, 5303883, 53038835, 4241841, 4241851, 4241861, 4241871, 4241881

Methods and compositions are provided for the use of an envelope polypeptide or a functional variant thereof from a lentivirus that is not HIV-1 as a molecular scaffold for HIV-1 epitopes. The HIV-1 epitopes can be recognized by HIV-1 binding antibodies, HIV-1 neutralizing antibodies and/or CD4-induced antibodies. Thus, methods are provided for detecting HIV-1 binding antibodies in a subject infected with HTV-1. Further provided are methods to determine an epitope for an HIV-1 binding antibody; methods to assay for an HIV-1 binding antibody; methods to identify a soluble CD4 mimic; methods to neutralize an non-HIV-1 virus; diagnostic assays to monitor HIV disease in a subject or to monitor the subject's response to immunization by a HIV vaccine; and methods to alter the neutralization potential of an HIV-1 derived CD4-induced antibody. Chimeric polypeptides, chimeric polynucleotides, kits, cells and viruses are also provided.

8647818, Feb 11, 2014

Feb 16, 2006

11/816624

George M. Shaw - Birmingham AL, US
Beatrice H. Hahn - Birmingham AL, US
Frederic Bibollet-Ruche - Birmingham AL, US
Peter D. Kwong - Washington DC, US

UAB Research Foundation, University of Alabama—Birmingham - Birmingham AL
The United States of America, as represented by the Secretary, Department of Health and Human Services (Hereinafter the Government) Office of Technology Transfer, National Institutes of Health - Washington DC

C12Q 1/70, A61K 39/00, A61K 39/12, A61K 39/21, A61K 39/38, C07K 16/00

435 5, 435339, 4353391, 5303883, 53038835, 4241841, 4241851, 4241861, 4241871, 4241881

Methods and compositions are provided which employ chimeric polypeptides having at least one heterologous epitope for a human immunodeficiency virus type 1 (HIV-1) neutralizing antibody. These chimeric polypeptides behave as molecular scaffolds which are capable of presenting the various heterologous HIV-1 epitopes. The invention demonstrates that a heterologous epitope recognized by the HIV-1 neutralizing antibody can be more fully exposed to neutralizing antibodies when presented within the backbone of the chimeric polypeptide than when the epitope is presented within the context of an HIV-1 backbone. Polynucleotides encoding these chimeric polypeptides are also provided. Immunogenic compositions are provided which comprise a chimeric polypeptide having at least one heterologous epitope that interacts with an HIV-1 neutralizing antibody. Immuno genie compositions comprising chimeric polynucleotides encoding the chimeric polypeptides of the invention are also provided. Vaccines comprising such immunogenic compositions are also provided.

2012003, Feb 9, 2012

Feb 6, 2009

12/866723

Peter D. Kwong - Washington DC, US
Gary J. Nabel - Washington DC, US
George Shaw - Birmingham AL, US
William Schief - Seattle WA, US
Zhi-yong Yang - Potomac MD, US
Tongqing Zhou - Boyds MD, US
Lei Chen - Rockville MD, US
Young Do Kwon - Rockville MD, US

A61K 39/21, C07K 14/195, C07K 14/37, C07K 14/005, A61P 31/18, A61K 39/00, C07H 21/00, G01N 33/566, A61P 37/04, C07K 14/16, C07H 21/04

4241881, 530395, 530350, 536 2372, 4241841, 536 231, 4242081, 435 792

Disclosed are antigens that include a target epitope that is defined by atomic coordinates of those amino acids of the antigen that contact an antibody of interest that specifically binds the antigen. The disclosed antigens have between about 10% and about 90% of surface exposed amino acid residues located exterior of the target epitope substituted as compared to a wild-type antigen and less than about 10% of the non-surface exposed amino acid residues substituted as compared to a wild-type antigen. Also disclosed are nucleic acids encoding these antigens and methods of producing these antigens. Methods for generating an immune response in a subject are also disclosed. In some embodiments, the method is a method for treating or preventing a human immunodeficiency type 1 (HIV-1) infection in a subject.

2012008, Apr 12, 2012

Aug 23, 2011

13/137517

Barton F. Haynes - Durham NC, US
Feng Gao - Durham NC, US
Bette T. Korber - Oakland CA, US
Beatrice H. Hahn - Birmingham AL, US
George M. Shaw - Birmingham AL, US
Denise Kothe - Birmingham AL, US
Ying Ying Li - Birmingham AL, US
Julie Decker - Birmingham AL, US

DUKE UNIVERSITY - Durham NC
THE UNIVERSITY OF ALABAMA AT BIRMINGHAM RESEARCH FOUNDATION - Birmingham AL
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA - Oakland CA

A61K 39/21, A61P 31/18, C12N 15/63, C07K 14/16, C12N 15/49

4241881, 530350, 536 2372, 4353201, 4242081

The present invention relates, in general, to an immunogen and, in particular, to an immunogen for inducing antibodies that neutralizes a wide spectrum of HIV primary isolates and/or to an immunogen that induces a T cell immune response. The invention also relates to a method of inducing anti-HIV antibodies, and/or to a method of inducing a T cell immune response, using such an immunogen. The invention further relates to nucleic acid sequences encoding the present immunogens.

2013017, Jul 11, 2013

Mar 3, 2011

13/582319

George M. Shaw - Birmingham AL, US
Beatrice H. Hahn - Birmingham AL, US
Hui Li - Birmingham AL, US
Barton F. Haynes - Durham NC, US
Martin Markowitz - New York NY, US

Duke University - Durham NC
The UAB Research Foundation - Birmingham AL

A61K 39/21

4241881, 530350, 536 2372, 4353201, 5303879, 4352351

The present invention relates, in general, to HIV-1 and, in particular, to a molecular clone of HIV-1. The invention further relates to methods of inducing an immune response to HIV-1 in a patient and to immunogens suitable for use in such methods. The invention also relates to anti-HIV-1 antibodies and to methods of using same to prevent or treat HIV-infection.

6897301, May 24, 2005

Nov 8, 2002

10/290579

Beatrice H. Hahn - Birmingham AL, US
George M. Shaw - Birmingham AL, US
Feng Gao - Hoover AL, US

The UAB Research Foundation - Birmingham AL

C07H021/04

536 2372, 536 231, 435 5, 435 6, 435 912, 530324, 530350

The nucleotide sequences of the genomes of eleven molecular clones for non-subtype B isolates of human immunodeficiency virus type 1 are disclosed. The invention relates to the nucleic acids and peptides encoded by and/or derived from these sequences and their use in diagnostic methods and as immunogens.

2003016, Aug 28, 2003

Feb 18, 2003

10/369294

Beatrice Hahn - Birmingham AL, US
Feng Gao - Hoover AL, US
George Shaw - Birmingham AL, US
Preston Marx - Covington LA, US
Stephen Smith - Essex Fells NJ, US
Marie Georges-Courbot - Paris XV, FR
Chang Lu - Forest Hills NY, US

UAB Research Foundation

C12Q001/70, C07H021/04

435/005000, 536/023720

The nucleotide sequence and deduced amino acid sequences of the complete genome of a simian immunodeficiency virus isolate from a red-capped mangabey are disclosed. The invention relates to the nucleic acids and peptides encoded by and/or derived from these sequences and their use in diagnostic methods and as immunogens.